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For patients requiring multiple transfusions and patients with 
positive direct antiglobulin tests (DATs), an extended red blood 
cell (RBC) phenotype can provide valuable information and 
help to determine the risk of forming alloantibodies. In some 
instances, the phenotype may be used for prophylactic matching. 
Phenotyping in this patient population is often hindered by the 
presence of circulating donor cells and/or by a positive DAT. 
Several methods, such as EDTA glycine acid (EGA) treatment to 
remove IgG, hypotonic saline wash to separate autologous RBCs, 
or reticulocyte separation, are often used in these situations to 
isolate patient RBCs for serologic phenotyping. This study aimed 
to determine the accuracy of each RBC pretreatment method by 
comparing serologically determined antigen types with those 
predicted by RBC genotyping. Forty-eight peripheral blood 
samples from recently transfused patients were phenotyped 
for selected antigens in the Rh, Kell, MNS, Duffy, and Kidd 
systems. Treatment methods for the sample sets were reticulocyte 
separation (N = 12), EGA (N = 16), and hypotonic saline wash 
(N = 20). DNA was extracted using standard methods, and 
genotyping was performed using the HEA BeadChip panel. In 
addition, 21 samples positive for RBC-bound IgG were EGA-
treated up to two times. These samples were analyzed pre- and 
post-EGA treatment for RBC-bound IgG by tube DAT and by 
flow cytometry with fluorescein isothiocyanate–labeled anti-
human IgG. After reticulocyte separation, 3 of the 12 samples had 
discordant types with one antigen each: Fyb, N, and K; serologic 
results were negative compared with genotype-predicted positive 
phenotype results. The EGA-treated sample set showed one 
discordant type: Fyb; serologic results were negative compared 
with genotype-predicted positive phenotype results. Four of the 
20 samples had discordant types involving the following antigens: 
Fyb, N, e, and M; serologic results were negative compared 
with genotype-predicted positive phenotype results. After EGA 
treatment of 21 samples, 14 (67%) were negative for RBC-bound 
IgG by tube DAT, and 7 remained positive. Using flow cytometry, 
EGA treatment rendered only 4 samples negative, and 17 remained 
positive. In the antigen testing sample set of 48 samples, 10 of 
511 total antigen types tested were discordant. Discordant types 
were most frequent in the hypotonic saline wash sample set (N = 
6). In the flow cytometry sample set, 48 percent of the samples 
negative by tube DAT after EGA elution had detectable RBC-
bound IgG by flow cytometry. These findings suggest that caution 
should be taken when using phenotype results from all pretreated 
RBCs and support the use of RBC genotyping to predict RBC 
antigen expression in samples from recently transfused patients. 
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Red blood cell (RBC) phenotyping is valuable for trans-
fusion management of multiply transfused patients, including 
the determination of the risk of forming alloantibodies. 
Extended phenotype matching is most commonly used in 
situations where there is a need to avoid sensitization in a 
nontransfused patient1 or to avoid further alloimmunization in 
a patient who has already been sensitized.2–5 Phenotyping of 
patients in these situations is often hindered by the presence of 
circulating donor cells or by a positive direct antiglobulin test 
(DAT). Because a donor RBC can survive in circulation for up 
to 120 days, it is not recommended to phenotype individuals 
who have been transfused in the past 3 months.6 In addition, 
phenotyping with certain types of antisera may be hindered 
in patients with autoantibodies causing a positive DAT. In 
these scenarios, methods—such as EDTA glycine acid (EGA) 
treatment to remove IgG, hypotonic wash to separate autologous 
cells from patients with sickle cell disease, or microhematocrit 
centrifugation to isolate reticulocytes—are often used in an 
attempt to obtain a phenotype.6 The effectiveness of removing 
IgG from RBCs to obtain DAT-negative RBCs can vary between 
methods.7 With the increasing availability of RBC genotyping, 
more blood banks are using this testing to obtain a predicted 
RBC phenotype as an alternative to RBC pretreatments 
followed by serologic antigen typing.8 A RBC genotyping 
panel such as the U.S. Food and Drug Administration (FDA)-
approved PreciseType Molecular BeadChip9 (Immucor, 
Norcross, GA) can predict antigen status for many of the major 
clinically significant blood group systems (Table 1). Especially 
in patients with hemoglobinopathies, genotyping is a routine 
approach to obtaining an extended RBC phenotype.3,5,10 It has 
been previously documented that genotyping can provide 
more accurate RBC phenotype results than routine serology.11 
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A small study was performed to measure, by tube and flow 
cytometry, the effectiveness of EGA treatment in removing IgG 
from RBCs. This study aimed to compare the accuracy of the 
results obtained from the commonly used RBC pretreatment 
methods with the results from a genotype-predicted phenotype 
using the BeadChip platform.
Materials and Methods
This study was approved by the American Red Cross 
institutional review board. A total of 48 peripheral blood 
samples from recently transfused patients were phenotyped 
for RH, KEL, MNS, FY, and JK antigens (Table 2). RBC 
pretreatment methods included reticulocyte separation 
(N = 12), EGA treatment (N = 16), and hypotonic wash 
(N = 20). Serologic antigen typing was performed by the tube 
method with licensed antisera from various sources (American 
Red Cross, Gaithersburg, MD; Immucor). Genomic DNA was 
extracted from peripheral blood mononuclear cells using 
DNA Blood Mini Kits (Qiagen, Carlsbad, CA), and genotyping 
was performed per the manufacturer’s directions using the 
HEA BeadChip (Immucor) with a 96-well Veriti thermal 
cycler (Applied BioSystems, Foster City, CA), InSlideOut 
oven (Boekel Scientific, Feasterville, PA), and Array Imaging 
System (Immucor). The blood group antigens predicted by the 
genotyping panel are listed in Table 1. For the samples studied 
by flow cytometry and tube-DAT testing, 21 additional samples 
positive for RBC-bound IgG were EGA-treated (Gamma EGA 
kit, Immucor) until a negative tube DAT was obtained (up to 
two times). The samples were analyzed before and after EGA 
treatment for RBC-bound IgG by tube DAT (Immucor) and by 
flow cytometry (Becton Dickinson FACScalibur, San Jose, CA) 
with fluorescein isothiocyanate–labeled anti-human IgG (Life 
Technologies, Carlsbad, CA).
Results
Among the 147 antigen typing results in 12 samples 
tested after reticulocyte separation, 3 (2.0%) were discordant 
with 1 antigen each; 1 sample (R-1) phenotyped Fy(b–) and 
was predicted to be Fy(b+w) by genotyping, 1 sample (R-4) 
phenotyped N– and was predicted to be N+ by genotyping, 
and 1 sample (R-7) phenotyped K– and was predicted to be 
K+ by genotyping. Among the 116 antigen typing results in 
the 16 EGA-treated samples, 1 was discordant (0.8%); sample 
(E-12) phenotyped Fy(b–) and was predicted to be Fy(b+w) by 
genotyping. Among the 248 antigen typing results in the 20 
hypotonic wash samples, 6 (2.4%) were discordant; 2 samples 
(H-10, H-15) phenotyped Fy(b–) and were predicted to be 
Fy(b+) by genotyping, 2 samples (H-11, H-16) phenotyped N– 
and were predicted to be N+ by genotyping, 1 sample (H-18) 
phenotyped M– and was predicted to be M+ by genotyping, 
and 1 sample (H-16) phenotyped e– and was predicted to be 
e+ by genotyping (ruling out common e variants interrogated 
by the HEA BeadChip). The antigen typing results for all 
samples are shown in Table 2. For comparison of effectiveness 
of EGA treatment by tube-DAT and flow cytometry, 21 
samples were tested. Fourteen (67%) samples were negative 
for RBC-bound IgG by tube DAT and 7 were positive. When 
tested by flow cytometry, 4 (19%) samples were negative after 
EGA treatment, and 17 remained positive. Interestingly, of 
the 17 samples that were positive by flow cytometry, 10 were 
negative by tube DAT after EGA treatment.
Discussion
This study aimed to compare antigen types obtained after 
commonly used RBC pretreatments to RBC genotyping using 
an FDA-approved test. A total of 10 discordant results were 
discovered in 48 samples, with discordant types identified in 
each of the three treatment sets and with each discordant result 
being a false negative by phenotyping after RBC treatment. 
Discordant types (N = 6) were most frequently identified in 
the hypotonic wash sample set (N = 20), with 25 percent of 
samples being discordant with one or more antigens. The 
total number of antigens that were tested on these samples 
was 248, 2.4 percent of which were found to be discordant. 
Table 1. Blood group antigens predicted by the HEA BeadChip 
genotyping panel
Blood group system Antigens
RH C, c, E, e, V, VS
FY Fya, Fyb, Fyb silenced






KEL K, k, Kpa, Kpb, Jsa, Jsb
LU Lua, Lub
MNS M, N, S, s, U, UVAR*
*Includes UVAR (P2) and UVAR (NY).
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Table 2. Antigen typing results [positive (+), negative (0), or weak (+w)] for reticulocyte separation samples (R-1 through R-12), EDTA 
glycine acid (EGA)-treated samples (E-1 through E-16), and hypotonic saline wash samples (H-1 through H-20).
Sample C E c e M N S s K Fya Fyb Jka Jkb
R-1 + 0 + + 0 + 0 + 0 0 0/+w 0 +
R-2 + 0 0 + NT NT 0 + 0 + + + +
R-3 0 0 + + + + NT NT 0 NT NT 0 +
R-4 + 0 + + + 0/+ + + NT + 0 + +
R-5 0 0 + + + + 0 + 0 + 0 + +
R-6 0 0 + + + + 0 + NT 0 0 + 0
R-7 0 + + 0 + + + 0 0/+ 0 + + +
R-8 0 0 + + 0 + 0 + 0 0 0 + +
R-9 0 0 + + + + + + 0 0 0 + +
R-10 0 + + 0 0 + + + 0 + 0 + +
R-11 0 0 + + + 0 + + 0 0 0 + 0
R-12 0 + + + + + + + NT + + 0 +
E-1 NT NT NT NT NT NT + + NT 0 + + 0
E-2 NT NT NT NT NT NT 0 + NT + + + NT
E-3 NT NT NT NT NT NT 0 + NT 0 + + +
E-4 + 0 0 + 0 + 0 + NT + + 0 +
E-5 NT NT NT NT NT NT + 0 NT + + NT NT
E-6 NT NT NT NT NT NT 0 + NT 0 + NT NT
E-7 + + + + + + 0 + NT + + + +
E-8 0 0 + + + 0 + + NT + + + 0
E-9 NT NT NT NT NT NT + 0 NT + + NT NT
E-10 + 0 + + + 0 + + NT 0 + 0 +
E-11 + 0 + NT 0 + + 0 NT + 0 0 +
E-12 NT NT NT NT NT NT 0 + NT + 0/+w + +
E-13 NT NT NT NT NT NT + + NT + 0 + +
E-14 NT NT NT NT NT NT 0 + NT + + + 0
E-15 NT NT NT NT NT NT 0 + NT 0 + + 0
E-16 NT NT NT NT NT NT 0 + NT 0 + NT NT
H-1 + 0 + NT 0 + 0 + 0 0 + + +
H-2 + 0 + + 0 + 0 + 0 0 0 0 +
H-3 0 0 + NT NT NT 0 + 0 0 0 + 0
H-4 0 0 + NT + 0 + + 0 0 0 + 0
H-5 0 0 + + + NT 0 + NT 0 0 + +
H-6 + 0 0 NT + + 0 + 0 0 0 + 0
H-7 0 0 + NT + + + + 0 0 0 + 0
H-8 0 0 + + + + + + 0 0 0 + +
H-9 + 0 + + + + 0 + 0 0 0 + +
H-10 0 0 + + + 0 0 + 0 0 0/+ + +
H-11 0 0 + + NT 0/+ 0 + 0 0 0 + 0
H-12 + 0 + + + + 0 + 0 0 0 + +
H-13 0 + + + + + + 0 0 + 0 + 0
H-14 + 0 + + + + 0 + 0 0 + + +
H-15 0 0 + NT 0 + + + 0 0 0/+ + 0
H-16 0 + + 0/+ + 0/+ 0 + 0 + + + +
H-17 + 0 + + + + 0 + 0 0 0 + 0
H-18 0 0 + NT 0/+ + 0 + 0 0 0 + 0
H-19 0 0 + + + + 0 + 0 0 0 + 0
H-20 + 0 + + 0 + 0 + 0 0 0 0 +
Discordant antigens are highlighted in gray with serologic result presented first and genotype-predicted phenotype after the slash. Antigens not tested by 
serology are indicated by NT.
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One discordant type was noted in the EGA-treated sample set 
(N = 16), with 6 percent of samples being discordant with one 
or more antigens and 0.8 percent of antigens tested (N = 116) 
being discordant. Three discordant types were noted in the 
reticulocyte-separated sample set (N = 12), with 25 percent 
of samples being discordant with one or more antigens and 
2 percent of total antigens tested (N = 147) being discordant 
(Figs. 1 and 2). 
Two of the 10 total discordant samples (1 reticulocyte 
separation, 1 EGA treatment) carried the missense variant 
c.265C>T in the ACKR1 gene, which encodes the FY antigens. 
This variant causes marked weakening of the Fyb antigen 
(Fyx phenotype), which can be weakly agglutinated by some 
commercial antisera but may be missed by others12 and is a 
common cause of Fyb typing discrepancies. This scenario 
may result in interpreting a patient with Fyx as Fy(b–) and 
may complicate provision of antigen-matched RBCs for 
transfusion-matching protocols requiring FY status. More 
recently, a similar variant was found that can cause weakening 
of Fya.13
Furthermore, flow cytometry of EGA-treated RBCs 
suggests that samples negative by tube DAT after EGA elution 
may still have trace amounts of RBC-bound IgG detectable 
only by flow cytometry.14 It is therefore critical that controls for 
residual IgG coating be performed with each sample treated 
with EGA (if the treatment is intended to remove RBC-bound 
IgG for the purpose of antigen testing), since the effectiveness 
of the treatment on removal of IgG may be different for 
individual patient samples.
A recent survey of current practices for providing blood 
to patients with warm-reactive autoantibodies (WAA) showed 
that 75 percent of laboratories surveyed provided phenotype-
matched or genotype-matched RBCs for transfusion, with 
80 percent of laboratories using RBC genotyping as part of 
an antibody workup in patients with WAA.15 These findings 
suggest that caution should be taken when using phenotype 
results from treated RBCs to confirm suspected antibody 
specificities or to provide extended matching for future 
transfusions. This study did not rule out the presence of 
uncommon variants in the 10 samples with discordant antigen 
types. The discrepancies described here were associated with 
false-negative typings after cell treatment. False-negative 
results may cause the laboratory to misidentify an antibody 
specificity and distract the tester from identifying the true 
specificity, especially in patients with variant antigens when 
the phenotype is being used to help rule in or out certain 
antibodies. 
For example, in our study, one sample was discrepant for 
e (serologic E+e–, genotype predicted E+e+); if the patient 
was receiving blood matched for RH antigens, e– blood would 
have been sourced, increasing the complexity because of the 
lower incidence of the e– phenotype. If this testing were to be 
used to provide antigen-matched blood, it could potentially 
cause delays in blood selection because of the perceived need 
for more antigens to be negative than is needed. 
This study shows the advantages of using genotyping 
to predict RBC antigen expression and confirms that it is 
preferable in difficult patient samples. Our results show that 
RBC manipulation can result in serologic/genotypic antigen 
discrepancies and suggest that if extrapolated to general 
clinical use, additional antigen discrepancies—some with 
significant clinical impact—could be recognized.
Fig. 1. Concordance of samples tested by treatment. EGA = EDTA 
glycine acid–treated sample set; Retic = reticulocyte-separated 










Fig. 2. Total discordant antigens per treatment. EGA = EDTA 
glycine acid–treated sample set; Retic = reticulocyte-separated 
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